Vetoquinol (VETO) - Total Liabilities
Based on the latest financial reports, Vetoquinol (VETO) has total liabilities worth €158.29 Million EUR (≈ $185.05 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore VETO cash generation efficiency to assess how effectively this company generates cash.
Vetoquinol - Total Liabilities Trend (2004–2024)
This chart illustrates how Vetoquinol's total liabilities have evolved over time, based on quarterly financial data. Check VETO financial resilience to evaluate the company's liquid asset resilience ratio.
Vetoquinol Competitors by Total Liabilities
The table below lists competitors of Vetoquinol ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Service Stream Ltd
AU:SSM
|
Australia | AU$533.37 Million |
|
Asana Inc
NYSE:ASAN
|
USA | $652.07 Million |
|
Fujian Septwolves Industry Co Ltd
SHE:002029
|
China | CN¥2.90 Billion |
|
Jiangsu Olive Sensors High-Tech Co Ltd
SHE:300507
|
China | CN¥1.52 Billion |
|
Lg Electronics Pref
KO:066575
|
Korea | ₩40.25 Trillion |
|
Shenzhen Sunxing Light Alloys
SHG:603978
|
China | CN¥2.54 Billion |
|
CareDx Inc
NASDAQ:CDNA
|
USA | $121.17 Million |
|
Rayhoo Motor Dies Co Ltd
SHE:002997
|
China | CN¥4.11 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Vetoquinol's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Vetoquinol stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vetoquinol's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vetoquinol (2004–2024)
The table below shows the annual total liabilities of Vetoquinol from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €168.20 Million ≈ $196.64 Million |
+1.86% |
| 2023-12-31 | €165.12 Million ≈ $193.04 Million |
-1.23% |
| 2022-12-31 | €167.19 Million ≈ $195.46 Million |
-8.75% |
| 2021-12-31 | €183.21 Million ≈ $214.19 Million |
-33.20% |
| 2020-12-31 | €274.26 Million ≈ $320.64 Million |
+118.56% |
| 2019-12-31 | €125.49 Million ≈ $146.71 Million |
+22.43% |
| 2018-12-31 | €102.50 Million ≈ $119.83 Million |
-5.31% |
| 2017-12-31 | €108.24 Million ≈ $126.55 Million |
-11.78% |
| 2016-12-31 | €122.70 Million ≈ $143.45 Million |
-0.23% |
| 2015-12-31 | €122.98 Million ≈ $143.78 Million |
-18.54% |
| 2014-12-31 | €150.97 Million ≈ $176.50 Million |
+30.28% |
| 2013-12-31 | €115.88 Million ≈ $135.47 Million |
-9.77% |
| 2012-12-31 | €128.43 Million ≈ $150.15 Million |
+20.00% |
| 2011-12-31 | €107.02 Million ≈ $125.12 Million |
-14.50% |
| 2010-12-31 | €125.18 Million ≈ $146.34 Million |
-2.75% |
| 2009-12-31 | €128.72 Million ≈ $150.49 Million |
+29.53% |
| 2008-12-31 | €99.38 Million ≈ $116.18 Million |
-1.15% |
| 2007-12-31 | €100.53 Million ≈ $117.53 Million |
+1.06% |
| 2006-12-31 | €99.47 Million ≈ $116.30 Million |
-11.89% |
| 2005-12-31 | €112.90 Million ≈ $131.99 Million |
+6.93% |
| 2004-12-31 | €105.58 Million ≈ $123.44 Million |
-- |
About Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal … Read more